Continuous glucose monitoring represents a paradigm shift in Type 2 diabetes management, with over 500 clinical trials demonstrating consistent benefits across patient populations. This technology provides unparalleled glucose data that transforms how patients understand and manage their condition, whether they have pre-diabetes, take oral medications alone, or use any insulin regimen. Available options include the Dexcom G7, Abbott Libre, Eversense 365 implantable sensor, and over-the-counter solutions like Abbott Lingo and Dexcom Stelo for non-insulin users, offering valuable insights. For insulin-using patients with type 2 diabetes, CGM serves as the foundation for modern hybrid closed-loop systems from Medtronic 780G, Insulet Omnipod 5, Tandem Control IQ and others that are available on the market, improving clinical outcomes while providing actionable insights into how daily choices affect glucose levels, making it standard of care for any Type 2 patient using insulin.